期刊文献+

胞浆轻链免疫荧光结合荧光原位杂交检测初诊多发性骨髓瘤del(17p13)及其临床意义 被引量:8

Detection of del(17p13)among newly diagnosed multiple myeloma cases using cytoplasmic light chain immunofluorescence combined with FISH and its clinical significance
原文传递
导出
摘要 目的应用胞浆轻链免疫荧光结合荧光原位杂交技术(cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization,cIg-FISH)检测多发性骨髓瘤的染色体异常情况,并分析del(17p13)与新诊断的多发性骨髓瘤(newly diagnosed multiple myeloma,NDMM)患者的临床资料的关系、治疗反应及其对预后的影响。方法收集2010年12月至2018年6月收治的198例NDMM患者的临床资料,应用cIg-FISH技术,采用特异性探针(TP53)对其骨髓标本进行检测,分析其染色体异常情况,并与患者的临床指标进行相关性分析。结果在198例NDMM患者中,共发现19例(9.6%)存在del(17p13),伴有del(17p13)患者的总生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS)较不伴有del(17p13)患者差异有统计学意义(P<0.01)。Del(17p13)的多发性骨髓瘤患者采用硼替佐米为主方案与非硼替佐米为主方案相比,其OS和PFS差异均无统计学意义(OS:P=0.873;PFS:P=0.610)。结论cIg-FISH技术是一种简单方便的检测多发性骨髓瘤核型异常的技术。del(17p13)是多发性骨髓瘤患者不良的预后因素,硼替佐米不能改善伴有del(17p13)的生存劣势。 Objective To detect chromosomal aberrations by using cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization(cIg-FISH),and to explore the correlation of del(17p13)with clinical characteristics,drug response and prognosis among patients with newly diagnosed multiple myeloma(NDMM).Methods Clinical data of 198 cases of NDMM was collected.cIg-FISH and a specific probe(TP53)were used to detect karyotypic abnormalities in bone marrow samples derived from the patients.Correlation between karyotypic abnormalities and clinical data was analyzed.Results Nineteen of the 198 patients(9.6%)were found to have a karyotype involving del(17p13).The overall survival(OS)and progression-free survival(PFS)for patients with or without del(17p13)was significantly different(P<0.01).No significant difference was found in OS and PFS between patients carrying a del(17p13)on bortezomib and non-bortezomib regimen(OS:P=0.873;PFS:P=0.610).Conclusion cIg-FISH is a simple and convenient method for the detection of karyotypic anomalies in multiple myeloma.Del(17p13)is an indicator for poor prognosis for multiple myeloma patients.Bortezomib cannot improve the survival disadvantage of del(17p13).
作者 陆秀盼 陈丽娟 史青林 仇海荣 李建勇 郭睿 Lu Xiupan;Chen Lijuan;Shi Qinglin;Qiu Hairong;Li Jianyong;Guo Rui(Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing,Jiangsu 210029,China)
出处 《中华医学遗传学杂志》 CAS CSCD 2020年第10期1087-1091,共5页 Chinese Journal of Medical Genetics
基金 国家自然科学基金(81670199) 江苏省重点人才项目(ZDRCA2016015)。
关键词 多发性骨髓瘤 del(17p) 预后 Multiple myeloma del(17p) Prognosis
  • 相关文献

参考文献3

二级参考文献8

  • 1Zhan FH, Barlogie B, John DSJr. Gene expression profiling defines a high-risk entity of multiple myeloma. J Cent South Univ (Med Sei), 2007, 32:192-203.
  • 2Sawyer JR, Tricot G, Mattox S, et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of perieentromeric heterochromatin. Blood, 1998, 91:1732-1741.
  • 3Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 Kip1 and an aggressive clinical course in multiple myeloma. Hematology, 2005, 10: 117-126.
  • 4Zhan F, Colla S, Wu X, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kipl-dependent and -independent mechanisms. Blood, 2007,109 : 4995-5001.
  • 5Fonseca R, Van Wier SA, Chng WJ, et al. Low level amplification (duplication) of 1q21 in myelorna and prognosis: the role of CKS1B. Blood, 2005,106: 185a.
  • 6Chang H, Qi X, Trieu Y, et al. Multiple myeloma patients with CKSIB gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol, 2006, 135: 486-491.
  • 7Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia, 2006, 20: 2034-2040.
  • 8N. Worel,H. Greinix,J. Ackermann,H. Kaufmann,E. Urbauer,P. H?cker,H. Gisslinger,K. Lechner,P. Kalhs,J. Drach. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma[J] 2001,Annals of Hematology(6):345~348

共引文献388

同被引文献84

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部